Clinical trials: Healthy Individual
HIV Infections
A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV
This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single dose administration of VH4527079 by subcutaneous (SC) injection or by intravenous (IV) infusion in healthy adult participants and multiple dose…
- Trial name
- NCT06652958
- Testing
- VH4527079
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy Volunteers, Overweight
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
The purpose of this study is to investigate how safe, and how well tolerated, the new study drug NNC0480-0389 is when it is given together with semaglutide.
- Conditions
- Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04259801
- Testing
- NNC0480-0389, Semaglutide
- Where
- Netherlands
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers
Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®
This study design is a randomized, double-blind, intra-individual controlled, single-center, phase 1 healthy volunteer study. Subjects who voluntarily signed the informed consent and are judged to be eligible for this study will…
- Trial name
- NCT03796351
- Testing
- MT10107, Botox
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Medy-Tox
Healthy
A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers
The purpose of this study is to evaluate the bioequivalence of a fixed dose combination (FDC) tablet of canagliflozin and metformin immediate release (IR) in comparison with the individual components of canagliflozin and…
- Trial name
- NCT01463228
- Testing
- A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Participants
Novel Energy Metabolic Signaling Molecule With Therapeutic Potential
Altogether a 25-day study. First 4 days non-blinded with water before 0-control blood samples (Day0). Thereafter blinded for 21 days (3 weeks). Study group was apparently healthy 50-60 -year-old males and females (N=27).
- Trial name
- RH013001 (NCT04713319)
- Testing
- Panavital
- Where
- Finland
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Petteri Hirvonen
Joint Pain
Move Study in Healthy Aging People
Bone and muscle losses occur during ageing leading to increased risk of osteoporosis (there are more than 200 million people affected by osteoporosis worldwide), sarcopenia, loss of functionality and mobility.
- Trial name
- NCT02276183
- Testing
- Nutrition intervention, test formula, progressive physical activity
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
COVID-19
Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated
This is a randomized, double-blind, active-controlled phase Ⅲ clinical trial.The purpose of this study is to evaluate the immunogenicity and safety of one booster dose of trivalent COVID-19 vaccine (vero cell), inactivated…
- Trial name
- NCT05433272
- Testing
- Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain, COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Colombia
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech (Colombia) S.A.S.
Acute Kidney Injury, Renal Insufficiency
A Methodological Study to Learn More About Kidney Function in Healthy People and in People With Reduced Kidney Function
The main purpose of this study is to investigate how reliable a test assessing the renal functional reserve (RFR) and the maximum glomerular filtration rate (maxGFR) are.
- Trial name
- NCT07368712
- Testing
- No investigational study intervention
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- Bayer
Healthy
A Study in Healthy People to Compare Two Tablet Formulations of Pramipexole
The goal of this study is to find out whether pramipexole tablets made at two different production sites are handled in the same way by the body.
- Trial name
- NCT07727785
- Testing
- Sifrol®, Mirapex®
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteer Study
Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
This study will assess comparative bioavailability and effect of food on a prototype fixed-dose combination (FDC) of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in healthy subjects
- Trial name
- NCT06204679
- Testing
- Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Healthy
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers
The purpose of this study is to evaluate the bioequivalence of fixed dose combination (FDC) tablets of canagliflozin and metformin immediate release (IR) in comparison with the individual components of canagliflozin and metformin…
- Trial name
- NCT01454622
- Testing
- A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy, Obesity
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
The primary objective of this trial is to assess bioequivalence of two formulations of survodutide (formulation A and formulation B6) after multiple-dose treatment in male and female trial participants living with overweight or…
- Conditions
- Healthy, Obesity, Overweight
- Trial name
- NCT07407348
- Testing
- Formulation A, Formulation B6
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese
This is the first clinical trial with LEO 142397. The purpose of the trial is to assess the safety and tolerability of LEO 142397, along with the pharmacokinetics (what the body does to the drug) and the pharmacodynamics (what…
- Trial name
- NCT03995550
- Testing
- LEO 142397
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- LEO Pharma
Healthy
A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood
The main objective of this trial is to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of BI 1291583 at steady state.
- Trial name
- NCT06917872
- Testing
- BI 1291583, erythromycin
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Different Doses of BI 3814916 Are Tolerated by Healthy People
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3814916 in healthy male and female trial participants.
- Trial name
- NCT07486115
- Testing
- BI 3814916
- Where
- Belgium
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Study to Evaluate the Effect of Botanical Dietary Supplements on Inflammation in Healthy People
The purpose of the study is to evaluate the effect of botanical dietary supplements on inflammation in healthy people with different genetic responses to inflammation.
- Trial name
- NCT00303238
- Testing
- Rose hips extract + blueberry/blackberry extract + resveravine, Rose hips extract + blueberry/blackberry extract + Aframomum melegueta extract, Rose hips extract + resveravine + Aframomum melegueta extract
- Where
- 8 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Access Business Group
Healthy
Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers
Incidence of visual phenomena, heart rate at rest, safety (with particular emphasis on QT analysis of ECGs), and pharmacokinetic parameters
- Trial name
- NCT02264015
- Testing
- Cilobradine, low, film-coated tablets, Cilobradine, high, film-coated tablets, Moxifloxacin, film-coated tablets
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Inflammatory Gastrointestinal Diseases
A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons
Interleukin (IL)-6 is a cytokine produced in response to infection and tissue damage. IL-6 is believed to act as a key mediator in chronic inflammation and autoimmune diseases such as inflammatory bowel diseases.
- Trial name
- NCT06298032
- Testing
- Olamkicept Part A, Olamkicept Part B
- Where
- Germany
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Ferring Pharmaceuticals
HCV Infection
Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection
Hepatitis C virus (HCV) is an enveloped, single strand, positive sense RNA flavivirus. Infection by HCV is typically chronic, although an estimated ~10-20% may spontaneously clear the virus.
- Trial name
- NCT03674125
- Testing
- GLS-6150
- Where
- 2 sites in South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Hepatic Impairment, Healthy, Hepatic Insufficiency
A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease
The purpose of this study to understand how the study medicine atirmociclib behaves in the body and how safe it is for people with different levels of liver health.
- Conditions
- Hepatic Impairment, Healthy, Hepatic Insufficiency, Healthy Adults
- Trial name
- NCT07677358
- Testing
- Atirmociclib
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer